Macular degeneration is an eye disease that gradually damages the small central zone of the retina you rely on for reading, recognizing faces, and driving. It is a leading cause of central vision loss in American adults over 50, and it is widely misunderstood: it does not cause total blindness, it exists in two very different forms, and only one of them becomes urgent when symptoms change suddenly. In this article you will learn how dry and wet age-related macular degeneration differ, which warning signs deserve a same-week phone call, how eye doctors confirm the diagnosis with imaging rather than blood work, and what current treatments can and cannot do. You will also see where routine lab results fit in, because the risk profile of this condition overlaps with heart and metabolic health.
What macular degeneration does to your sight
The retina lines the back of the eye like film in a camera. At its center sits the macula, a patch a few millimeters wide packed with the photoreceptor cells that deliver fine detail and color. Everything you read and every face you recognize is processed there. Age-related macular degeneration, usually shortened to AMD, is the progressive breakdown of that patch.
Central vision goes, peripheral vision stays
This is the single most reassuring fact about the disease. AMD attacks the macula, not the rest of the retina. The wide outer field of view that lets you notice a step, a doorway, or movement at your side is served by a different part of the retina and is generally preserved. That is why the National Eye Institute states plainly that AMD does not cause complete blindness, even in its advanced stages.
What people do lose is the middle of the picture: a face with a smudge where the eyes and mouth should be, a line of text with a word missing. That can end independent driving and make reading exhausting, which is a serious loss, but it is a different outcome from darkness.
How the disease is staged
Eye doctors describe AMD as early, intermediate, or late. Early AMD usually causes no symptoms and is spotted only because small yellowish deposits called drusen appear under the retina during an exam. Intermediate AMD means larger drusen and sometimes pigment changes, often still with near-normal vision. Late AMD is where sight is genuinely threatened, and it takes one of two shapes.
Dry and wet AMD are two different problems
Confusing these two forms is the most common mistake patients make, and it has consequences: the treatments, the urgency, and the speed of change are not the same.
Dry, or atrophic, AMD
Dry AMD accounts for the large majority of cases. Waste deposits build up beneath the retina, the supporting cell layer thins, and photoreceptors slowly die off, typically over years. Its advanced stage is called geographic atrophy: well-defined patches where retinal tissue has disappeared, expanding outward and eventually crossing the center of vision.
Wet, or neovascular, AMD
Wet AMD is less common but far more abrupt. Abnormal, fragile blood vessels grow up under the macula and leak fluid or blood, lifting and distorting the retina, so vision can change over days or weeks rather than years. It is the form behind most rapid, severe central vision loss, and also the form with the most effective treatment when caught early.
| Feature | Dry (atrophic) AMD | Wet (neovascular) AMD |
|---|---|---|
| Share of cases | Roughly 8 in 10 | Roughly 1 to 2 in 10 |
| What is happening | Deposits accumulate and retinal cells thin out | Abnormal blood vessels grow and leak |
| Typical pace | Years, sometimes decades | Days to weeks once it starts |
| Hallmark symptom | Slowly growing blur or blank spot in the center | Sudden distortion, straight lines that bend |
| Main treatment | Supplements at the intermediate stage; complement inhibitors for geographic atrophy | Anti-VEGF injections into the eye |
| How urgent | Routine monitoring | Urgent, treat within days |
One more point people often miss: dry AMD can convert to wet AMD, so anyone living with the dry form needs to know the warning signs, which is the entire purpose of home monitoring.
Symptoms and the early warning signs that matter
Early AMD is usually silent. By the time symptoms are obvious the disease has been present for a while, which is why routine dilated eye exams after 50 beat waiting for something to feel wrong. Symptoms worth attention include:
- Straight lines that look wavy, bowed, or broken, an effect doctors call metamorphopsia
- A blurred, gray, or blank patch sitting in the middle of what you are looking at
- Needing much brighter light to read than you used to
- Slow recovery of sight when you move from bright sunlight into a dim room
- Colors that seem washed out, or faces that are hard to recognize across a room
The Amsler grid, and how to use it properly
The Amsler grid is a printed square of fine graph lines with a dot in the middle. Cover one eye, wear your usual reading glasses, hold the page at normal reading distance, stare at the central dot, and notice whether any part of the grid looks wavy, blurred, dark, or missing. Then repeat with the other eye. Testing one eye at a time is the whole point, because a healthy eye compensates so well that a person can lose considerable central vision in the other eye without noticing.
Done a few times a week, this thirty-second test is the most practical early-warning system available for AMD. New distortion on the grid is not something to save for your next annual visit.
When to see a doctor without waiting
Call an eye doctor the same day, or the next day at the latest, if you notice any of these:
- A sudden change in how straight lines look in one eye
- A new dark or gray spot appearing in the center of your vision
- A rapid drop in reading vision over days rather than months
- New distortion on your home grid that was not there last week
Sudden distortion is the classic signature of wet AMD, which responds far better when injections start early. Waiting weeks to see whether it settles allows fluid and bleeding to scar the macula, and scar tissue does not recover.
How macular degeneration is diagnosed
One point deserves no ambiguity: AMD is diagnosed by looking at the retina, not by testing blood. No blood test confirms or rules out macular degeneration.
The eye exam and the imaging
A dilated eye exam comes first. Drops widen the pupil so the ophthalmologist can inspect the macula directly and look for drusen, pigment changes, atrophy, or fluid. Optical coherence tomography, almost always called OCT, then produces a cross-section image of the retina layer by layer without touching the eye. OCT shows whether fluid is present, the practical dividing line between dry and wet disease. If leakage is suspected, a dye-based angiogram or a dye-free OCT angiography maps the abnormal vessels.
The same dilated visit is efficient in another way: it lets the ophthalmologist also evaluate the optic nerve changes that signal glaucoma. Lens clouding blurs vision in the same age group, which is why people investigated for macular degeneration are often told at the same visit that they are developing a cataract in one or both eyes. These reports use Latin shorthand, so it helps to recognize the abbreviation OD for the right eye.
Where lab results honestly fit in
Blood work does not diagnose AMD. What it can do is describe the health background against which the disease develops, because the risk factors overlap with cardiovascular and metabolic ones. A 2025 pooled analysis of eighteen studies found smoking, high blood pressure, cardiovascular disease, and diabetes each associated with a higher chance of having AMD, while cholesterol and triglyceride levels were not.
A doctor managing overall risk may therefore already be tracking high blood pressure and long-term blood sugar in anyone living with diabetes, which usually means ordering a glycated hemoglobin test. Many patients this age also review a standard lipid panel and, when chronic inflammation is a question, high-sensitivity CRP testing. None of those numbers say anything about your macula: they describe the terrain, not the eye.
One genuine lab connection does exist, and it comes from treatment rather than diagnosis. The AREDS2 supplement used in macular degeneration contains a high daily dose of zinc, and sustained high zinc intake can lower copper. That is why the formula includes copper, and why some physicians occasionally check zinc blood levels alongside copper blood levels in long-term users, particularly those also taking other zinc products.
Risk factors you can change and ones you cannot
Age, genetics, and family history
Age is the dominant factor; macular degeneration is uncommon before 50 and becomes steadily more frequent afterward. Genetics matter substantially, so a parent or sibling with AMD is a good reason to mention family history and start exams earlier. Genetic testing is not routine, because knowing your risk variants does not currently change what a doctor would recommend.
Smoking and the shared cardiovascular picture
Smoking is the strongest modifiable risk factor, roughly doubling the odds in pooled analyses, and stopping lowers the risk over time. Blood pressure and cardiovascular disease also track with AMD, which fits what is known about the choroid, the vessel-rich layer feeding the macula. Diet matters too: dark leafy greens supply lutein and zeaxanthin, the pigments concentrated in the macula, and oily fish provides omega-3 fatty acids. Sunglasses and a healthy weight round out advice that is unglamorous and cheap.
Treatment options available today
AREDS2 supplements, and who they are actually for
The AREDS2 formula combines vitamin C, vitamin E, zinc, copper, lutein, and zeaxanthin. It is not a general eye vitamin and it is not preventive. It is intended for people who already have intermediate AMD in one or both eyes, or late AMD in one eye, and its purpose is to reduce the chance of progressing to the late stage. In early AMD the benefit is very small; with no AMD at all there is no evidence of benefit. Beta-carotene was removed from the original formula because it raised lung cancer risk in current and former smokers, so anyone with a smoking history should confirm the product they buy is the AREDS2 version. The copper is there deliberately, because the high zinc dose can otherwise deplete it.
Anti-VEGF injections for wet AMD
Wet AMD is treated with medicines injected into the eye that block vascular endothelial growth factor, the signal driving abnormal vessel growth. The injection takes seconds under numbing drops and is routinely tolerated, even though the idea alarms most people. These drugs stop leakage, dry the retina, and in many patients recover some lost letters on the eye chart. They are not a cure, and treatment continues indefinitely.
The main development of recent years is not stronger drugs but longer gaps between visits. Newer agents, including a bispecific antibody that blocks a second signaling pathway alongside VEGF and a higher-dose version of an established drug, let many patients stretch to twelve or sixteen weeks between injections with the same vision results. For someone arranging transport to a clinic every month, that is a real quality-of-life change.
Complement inhibitors for geographic atrophy
Until recently there was nothing to offer for advanced dry AMD. Two drugs that dampen the complement system, part of the immune system implicated in retinal damage, were approved in the United States in 2023 for geographic atrophy. They are given as repeated injections into the eye.
They deserve an honest description. In trials they slowed the expansion of atrophic patches compared with sham injections, but they did not improve vision, and the published evidence shows no measurable benefit on visual acuity at one year. One of them was also linked to a higher chance of developing the wet form. They are a real first step for a stage that previously had none, and a decision to weigh carefully with a retina specialist rather than an obvious win.
Low vision rehabilitation
This is the most underused part of AMD care. Low vision services provide magnifiers, high-contrast lighting, screen readers, eccentric viewing training that teaches you to use healthy retina just off-center, and home adaptations. Ask for a referral as soon as reading becomes hard work.
Living well with reduced central vision
Most people with macular degeneration keep enough sight to live independently, and much of the outcome depends on adaptations rather than medicine. Task lighting placed beside and slightly behind you cuts glare, and high-contrast markings on stairs and stove dials reduce accidents. Audiobooks, large-print materials, and voice assistants preserve the reading habit. Driving is the hardest conversation, and it is worth having early with family and your eye doctor rather than after an incident. Depression is common after a diagnosis that threatens independence, and it is treatable, so mention it.
Latest scientific advances
Research on macular degeneration has moved quickly since 2023. Here is what recent work found and what it means in practice.
A 2024 review in a major general medical journal summarized the field, confirming that AMD affects roughly twenty million people in the United States and that older age, genetics, and smoking remain the central drivers. What this means for you: the picture your doctor describes is well established, and the advice about smoking is not a formality.
A 2023 review that pooled all the good-quality trials on the question looked at antioxidant vitamin and mineral supplements. It concluded that they probably do slow progression to late AMD, and that the benefit is concentrated in people who already have intermediate disease. What this means for you: if an eye doctor has told you that you have intermediate AMD, the formula is worth discussing; if your exam was normal, it is not.
Two analyses published in 2023 and 2024 examined the complement inhibitors approved for geographic atrophy. Both found these drugs reduce how fast atrophic patches grow, and neither found clear improvement in how well people actually see at one year. One noted that monthly dosing of one agent raised the chance of developing the wet form. What this means for you: genuinely new options for a stage that had none, but they slow damage rather than restore sight.
Two sets of 2024 trial results point the same way in wet AMD. A large trial of a higher-dose anti-VEGF drug found that patients treated every twelve or sixteen weeks saw as well as those treated every eight weeks at the standard dose. Two-year results from matched trials of a newer bispecific antibody, a molecule that blocks two signals at once, showed most patients extended to twelve weeks or longer between injections with comparable vision gains. What this means for you: wet AMD care is moving toward less frequent treatment, not more, though the right interval depends on how your own eye behaves.
Finally, a 2025 pooled analysis of risk factors confirmed that smoking, high blood pressure, cardiovascular disease, and diabetes are each associated with AMD, while cholesterol and triglyceride levels are not. What this means for you: cardiovascular care is worth doing for many reasons, but a cholesterol number is not a macular degeneration score, and no lab panel replaces an eye exam.
Glossary
| Term | Definition |
|---|---|
| Macula | The small central area of the retina responsible for sharp, detailed central vision such as reading and recognizing faces. |
| Retina | The light-sensitive tissue lining the back of the eye that converts light into nerve signals sent to the brain. |
| Drusen | Small yellowish deposits that collect under the retina. A few are common with age; larger or numerous ones indicate AMD. |
| Geographic atrophy | The advanced form of dry AMD, in which well-defined patches of retinal tissue have wasted away and stopped working. |
| Neovascular AMD | The medical name for wet AMD, meaning new abnormal blood vessels have grown under the macula and are leaking. |
| Anti-VEGF | A class of medicines injected into the eye that block vascular endothelial growth factor, the signal that drives abnormal vessel growth. |
| OCT | Optical coherence tomography, a painless scan that produces a cross-section image of the retina layer by layer. |
| Amsler grid | A printed grid of straight lines with a central dot, used at home one eye at a time to detect new distortion in central vision. |
| Metamorphopsia | The symptom of seeing straight lines as wavy, bent, or broken, often the first noticeable sign of wet AMD. |
| Complement system | A part of the immune system that helps clear damaged cells. Overactivity of this system is linked to retinal damage in AMD. |
Frequently asked questions
What are the first signs of macular degeneration?
In the earliest stage there are usually no signs at all, and the condition is found during a routine dilated eye exam. When symptoms do appear, the most common first complaints are needing brighter light to read, difficulty adjusting when moving from bright light into a dim room, and a subtle sense that print looks less crisp than it used to. Distortion of straight lines and a blank or gray patch in the center of vision generally come later, and distortion in particular should be reported quickly because it can signal the wet form.
What does vision look like with macular degeneration?
It is not a dark curtain or tunnel vision. The typical experience is that the center of the scene becomes blurred, smudged, or partly missing while everything around it stays visible. People often describe faces without features, words dropping out of a line of text, or a warped patch where a door frame bends. Because the surrounding field is unaffected, most people continue to move around their home confidently even when reading has become difficult.
Can macular degeneration be cured?
No treatment currently reverses AMD or restores retinal cells that have already been lost. Claims of a cure, including personal stories circulating online, are not supported by evidence. What treatment can do is meaningful: anti-VEGF injections stop leakage in wet AMD and frequently recover some vision, supplements reduce the chance of progression in intermediate disease, and newer complement inhibitors slow the spread of atrophy. Early detection changes outcomes far more than any supplement or diet.
Does everyone with macular degeneration go blind?
No. Most people with AMD never reach the advanced stage, and even those who do retain their peripheral vision, so complete blindness is not the usual outcome. The realistic concern is losing the central detail needed for reading, driving, and recognizing faces. Low vision rehabilitation, magnification, lighting, and assistive technology allow the large majority of people with advanced AMD to keep living independently.
How quickly does macular degeneration progress?
It varies enormously and depends on which form you have. Dry AMD usually progresses over many years, and some people stay at the early stage for the rest of their lives. Geographic atrophy expands more steadily once it begins. Wet AMD is the exception: it can change vision noticeably within days or weeks, which is precisely why sudden distortion warrants an urgent appointment rather than a wait-and-see approach.
Is macular degeneration hereditary?
Family history is one of the strongest known risk factors after age, and many genetic variants that raise susceptibility have been identified. Having an affected parent or sibling does not mean you will develop the disease, but it does mean earlier and more regular dilated eye exams are worthwhile. Genetic testing is not routinely offered, because the result would not currently change prevention or treatment recommendations.
Sources
- National Eye Institute, National Institutes of Health — Age-Related Macular Degeneration (AMD), 2024 — nei.nih.gov
- Cleveland Clinic — Macular Degeneration: symptoms, diagnosis and treatment, 2024 — my.clevelandclinic.org
- Centers for Disease Control and Prevention — About Common Eye Disorders, 2024 — cdc.gov
- Fleckenstein M, et al. — Age-Related Macular Degeneration: A Review — JAMA, 2024 — doi.org/10.1001/jama.2023.26074
- Evans JR, Lawrenson JG — Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration — Cochrane Database of Systematic Reviews, 2023 — doi.org/10.1002/14651858.CD000254.pub5
- Tzoumas N, et al. — Complement inhibitors for age-related macular degeneration — Cochrane Database of Systematic Reviews, 2023 — doi.org/10.1002/14651858.CD009300.pub3
- Wang H, et al. — Efficacy and safety of complement inhibitors in patients with geographic atrophy associated with age-related macular degeneration: a network meta-analysis of randomized controlled trials — Frontiers in Pharmacology, 2024 — doi.org/10.3389/fphar.2024.1410172
- Lanzetta P, et al. — Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial — The Lancet, 2024 — doi.org/10.1016/S0140-6736(24)00063-1
- Khanani AM, et al. — TENAYA and LUCERNE: two-year results from the phase 3 neovascular age-related macular degeneration trials of faricimab with treat-and-extend dosing in year 2 — Ophthalmology, 2024 — doi.org/10.1016/j.ophtha.2024.02.014
- Babaker R, et al. — Risk factors for age-related macular degeneration: updated systematic review and meta-analysis — Medicine, 2025 — doi.org/10.1097/MD.0000000000041599
Further reading
- High cholesterol: causes, symptoms, and treatments
- Vitamin E blood levels explained
- Vitamin C blood levels explained
- Homocysteine blood levels explained
- The abbreviation OS for the left eye
Understand your lab results with BloodSense
Macular degeneration is confirmed in an eye clinic, not in a laboratory, but the conditions that travel alongside it show up in ordinary blood work. Blood pressure records, a long-term blood sugar marker, a lipid panel, and zinc and copper levels in anyone taking a high-dose eye supplement all become easier to act on once you understand what the numbers mean. BloodSense reads your blood, urine, and stool results in plain language and shows you which values sit outside the usual range and why that might matter. It helps you understand your results, it does not diagnose, and it does not replace your doctor or your eye specialist.
